Hims & Hers CEO ‘disappointed,’ says Novo Nordisk ‘misleading the public’

Andrew Dudum, founder and CEO of Hims & Hers Health (HIMS), stated in a post to his X account: “We are disappointed to see Novo Nordisk (NVO) management misleading the public. In recent weeks, Novo Nordisk’s commercial team increasingly pressured us to control clinical standards and steer patients to Wegovy regardless of whether it was clinically best for patients. We refuse to be strong-armed by any pharmaceutical company’s anticompetitive demands that infringe on the independent decision making of providers and limit patient choice. We take our role of protecting the ability of providers and patients to control individual treatment decisions extremely seriously, and will not compromise the integrity of our platform to appease a third party or preserve a collaboration. The health and wellness of individuals always comes first. We will continue to offer access to a range of treatments, including Wegovy, to ensure providers can serve the individual needs of patients.”